ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

SURVEY: Cognitive Impairment II

Natural Bladder Control, Go Less and Live More

Vital Molecule Increases Cellular Energy and Improves Cognitive Function

Top Vitamin and Mineral Deficiencies — Are You at Risk?

How Pomegranate May Protect Against Cancer

Omega Fix for Obesity: How the Right Fats Fight Fat

Trimming the spare tire: Canola oil may cut belly fat

The Onion: Cancer Fighter and Food Preserver

Fighting Heartburn and Gerd Naturally – And Safely!

Probiotics improve cognition in Alzheimer's patients

 
Print Page
Email Article

Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: A randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety – Source: BMC Medicine, Aug 16, 2010

  [ 14 votes ]   [ Discuss This Article ]
By Alan G Wade, et al. • www.ProHealth.com • August 20, 2010


[Note: To read the full text of this article free, click HERE.]

Background: Melatonin [in regular and timed release form] is extensively used in the USA in a non-regulated manner for sleep disorders.

Prolonged release melatonin (PRM) is licensed in Europe and other countries for the short term treatment of primary insomnia in patients aged 55 years and over.

However, a clear definition of the target patient population and well-controlled studies of long-term efficacy and safety are lacking. It is known that melatonin production declines with age. Some young insomnia patients also may have low melatonin levels.

The study investigated:

• Whether older age or low melatonin excretion is a better predictor of response to PRM,

• Whether the efficacy observed in short-term studies is sustained during continued treatment,

• And the long term safety of such treatment.

Methods: Adult outpatients (791, aged 18-80 years) with primary insomnia, were treated with placebo (2 weeks) and then randomized, double-blind to 3 weeks with PRM or placebo nightly.

PRM patients continued whereas placebo completers were re-randomized 1:1 to PRM or placebo for 26 weeks with 2 weeks of single-blind placebo run-out.

Main outcome measures were sleep latency derived from a sleep diary, Pittsburgh Sleep Quality Index (PSQI), Quality of Life (World Health Organzaton-5) Clinical Global Impression of Improvement (CGI-I) and adverse effects and vital signs recorded at each visit.

Results:
On the primary efficacy variable sleep latency:

• The effects of PRM (3 weeks) in patients with low endogenous melatonin (6-sulphatoxymelatonin [6-SMT] 8 g/night) regardless of age did not differ from the placebo,

• Whereas PRM significantly reduced sleep latency compared to the placebo in elderly patients regardless of melatonin levels (-19.1 versus -1.7 min; P=0.002).

• The effects on sleep latency - and additional sleep and daytime parameters that improved with PRM - were maintained or enhanced over the 6-month period with no signs of tolerance.

Most adverse events were mild in severity with no clinically relevant differences between PRM and placebo for any safety outcome.

Conclusions:
• The results demonstrate short- and long-term efficacy and safety of PRM in elderly insomnia patients.

• Low melatonin production regardless of age is not useful in predicting responses to melatonin therapy in insomnia.

• The age cut-off for response warrants further investigation.

Source: BMC Medicine, Aug 16, 2010;8(1):51. PMID: 20712869, by Wade AG, Ford I, Crawford G, McConnachie A, Nir T, Laudon M, Zisapel N. CPS Research and Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK; Neurim Pharmaceuticals Ltd. and Department of Neurobiology, Faculty of Life Sciences, Tel Aviv University, Tel-Aviv, Israel. [Email: alangwade@fastmail.fm]





Post a Comment

Featured Products From the ProHealth Store
FibroSleep™ Melatonin Sublingual Tablets Vitamin D3 Extreme™


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

Melatonin Sublingual Tablets Melatonin Sublingual Tablets
Supports Deep, Restful Sleep Naturally
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%

Natural Remedies

Cocoa's Polyphenol Riches - All the Health Benefits without the Sugar, Calories or Guilt Cocoa's Polyphenol Riches - All the Health Benefits without the Sugar, Calories or Guilt
Coconut Oil - Healthy Gifts from the 'Tree of Life' Coconut Oil - Healthy Gifts from the 'Tree of Life'
Secret Nutrient for Radiant Skin Secret Nutrient for Radiant Skin
Herbal Inflammation Management for Whole Body Health Herbal Inflammation Management for Whole Body Health
Anti-Inflammatory Properties of Tart Cherry Anti-Inflammatory Properties of Tart Cherry

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map